On the assumption that enhancing endogenous NSC proliferation and their differentiation towards OPC→ODC cell lineage by physiological molecules (e.g., some suitable growth factors) in MS lesions could lead to a successful remyelination therapy, some authors have argued that EGF could theoretically be a promising candidate for such therapy as a physiological enhancer of NSC mobilization and OPC→ODC lineage differentiation [342,484]. This evidence concerns the gene EGF and myeloid sarcoma.